|Dr. Thomas J. Schuetz M.D., Ph.D.||Co-Founder, CEO & Director||454k||N/A||1961|
|Dr. Vered Bisker-Leib MBA, Ph.D.||Pres & COO||720k||N/A||1971|
|Dr. Susan Kalled Ph.D.||Chief Scientific Officer||445.5k||N/A||1961|
|Mr. Neil L. Lerner CPA||VP of Fin.||N/A||N/A||1967|
|Mr. Jonathan Anderman J.D.||VP, Head of Legal & Corp. Sec.||N/A||N/A||N/A|
|Anna Gifford||Communications Mang.||N/A||N/A||N/A|
|Dr. Peter F. Moesta Ph.D.||Interim Head of CMC||N/A||N/A||N/A|
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Compass Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.